MAVRIK MOTORS A DIVISION OF TRIDELTA INDUSTRIESBusiness Directories,Company Directories

Company Name: Corporate Name:	MAVRIK MOTORS A DIVISION OF TRIDELTA INDUSTRIES
Company Title:	Mavrik Motors inc
Company Description:	see this go daddy instantpage®! http://mavrikmotors.com. get yours free with a domain name at godaddy.com. site coming soon!!!!
Keywords to Search:
Company Address:	7333 Corporate Blvd,MENTOR,OH,USA
ZIP Code: Postal Code:	44060
Telephone Number:	2162551080 (+1-216-255-1080)
Fax Number:
Website:	mavrikmotors. com
Email:
USA SIC Code(Standard Industrial Classification Code):	753804
USA SIC Description:	Automobile Motor Rebuilding
Number of Employees:
Sales Amount:
Credit History: Credit Report:
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
SMYTHECRAMERCO.
TEC
MENS WEARHOUSE

Next company profile:
LUFT BROTHERS
LAKE BLUE INC
ADAM STOVICEK

Company News:

Egetis receives FDA Breakthrough Therapy Designation for tiratricol for . . .
Tiratricol has been granted Rare Pediatric Disease Designation (RPDD) which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval
Review Designation Policy: Priority (P) and Standard (S)
Standard review designation is assigned to applications for drugs that do not meet the priority review designation criteria A priority review designation will set a goal date for taking
Search Orphan Drug Designations and Approvals
The sponsor address listed is the last reported by the sponsor to OOPD *Exclusivity Protected Indications are shown for approvals from 01 01 2013 to the present *Data for the Date Designation
Tiratricol: First Approval | Drugs - Springer
Tiratricol received its first approval on 12 February 2025 in the European Union, for the treatment of peripheral thyrotoxicosis in patients with MCT8 deficiency (Allan-Herndon-Dudley Syndrome), from birth
Egetis Receives FDA Breakthrough Therapy Designation for Tiratricol for . . .
Egetis Therapeutics AB (publ) announced that the U S Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tiratricol, as a treatment for monocarboxylate transporter 8 (MCT8) deficiency
Egetis receives Breakthrough Therapy Designation from the FDA
Egetis Therapeutics has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for tiratricol for the treatment of MCT8 deficiency
Tiratricol in Drug Development: Applications and Regulatory Considerations
When considering Tiratricol for drug development, understanding regulatory considerations is paramount Certifications like GMP and adherence to standards such as Reach and FDA guidelines are non-negotiable for materials used in pharmaceutical manufacturing
Egetis concludes that demonstrating treatment effects on T3 . . . - Nasdaq
The Company intends to submit a New Drug Application (NDA) in the US for Emcitate® (tiratricol) for the treatment of monocarboxylate transporter 8 (MCT8) deficiency in mid-2023 under the Fast
Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review
Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need A process designed to expedite the
Egetis provides update on disease awareness and the Expanded Access . . .
The Food and Drug Administration (FDA) regulates the development and approval for marketing of medical products in the USA Before regulatory approval, it is not normally possible to prescribe a pharmaceutical under development outside of clinical trials